New combo therapy shows promise for tough lung cancer cases
Disease control
Completed
This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in 92 people with advanced non-small cell lung cancer whose cancer had worsened after erlotinib treatment. The goal was to find a safe dose and see if the combination could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC